CSIMarket Company Name, Ticker, Suppliers, else..
 
Plus Therapeutics Inc   (NASDAQ: PSTV)
Other Ticker:  
 
 
Price: $1.2201 $-0.02 -1.318%
Day's High: $1.25 Week Perf: -2.39 %
Day's Low: $ 1.22 30 Day Perf: 1.68 %
Volume (M): 5 52 Wk High: $ 2.67
Volume (M$): $ 7 52 Wk Avg: $1.60
Open: $1.22 52 Wk Low: $0.92



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 8
 Employees 14
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 1

Plus Therapeutics Inc
Plus Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative, targeted therapies for rare and difficult-to-treat cancers. Their focus is on creating novel drugs that can potentially improve outcomes for patients with limited treatment options. They aim to combine advanced drug delivery technologies with cutting-edge science to deliver more effective and personalized treatments.


   Company Address: 4200 Marathon Blvd Austin 78756 TX
   Company Phone Number: 255-7194   Stock Exchange / Ticker: NASDAQ PSTV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CATX   -3.28%    
UEEC        3.74% 
AGEN   -7.71%    
IMVT   -6.65%    
• View Complete Report
   



Clinical Study

Rising Hope in Neuro-Oncology Plus Therapeutics? Revolutionary Approach to Leptomeningeal Metastases Shines...

Published Mon, Nov 25 2024 12:30 PM UTC

At the recently concluded Society for Neuro-Oncology (SNO) Annual Conference in 2024, Plus Therapeutics presented compelling interim data from its ReSPECT-LM Phase 1 trial, examining the efficacy of Rhenium-186 nanoLiposome (186RNL) in patients suffering from leptomeningeal metastases. This groundbreaking research has the potential to reshape the therapeutic landscape for a ...
Clinical Study

Plus Therapeutics is pushing the frontiers of oncology with its latest research and clinical trial data, of...

Published Fri, Nov 22 2024 12:30 PM UTC

Revolutionizing Cancer Treatment: Plus Therapeutics Groundbreaking Advances in CNSide Assays and ReSPECT Clinical Trials for CNS Metastases Plus Therapeutics is pushing the frontiers of oncology with its latest research and clinical trial data, offering hope and innovative solutions to patients grappling with challenging metastatic conditions. At two prestigious conferences...
Clinical Study

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients wi...

Published Thu, Nov 21 2024 12:30 PM UTC

Unlocking New Horizons in Neuro-Oncology: Plus Therapeutics Pioneering Advances in Leptomeningeal Metastases and Glioblastoma MultiformePlus Therapeutics is making notable strides in the realm of neuro-oncology, showcasing their ground-breaking work across two pivotal areas: leptomeningeal metastases and glioblastoma multiforme (GBM). The company has recently shared signif...
Partnership

Plus Therapeutics Joins Forces with SpectronRx A Promising Partnership Amidst Market Struggles

Published Wed, Nov 6 2024 12:30 PM UTC

In a significant development for the biopharmaceutical sector, Plus Therapeutics Inc. (NASDAQ: PSTV) has announced a strategic manufacturing partnership with SpectronRx, focused on advancing their radiotherapeutic production capabilities. This collaboration is set to enhance Plus Therapeutics position in the competitive oncology market, particularly as they work towards the...
Clinical Study

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons ...

Published Tue, Oct 1 2024 11:30 AM UTC

News Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting In a pivotal presentation at the 2024 Congress of Neurological Surgeons Annual Meeting, Plus Therapeutics, Inc. disclosed significant updates regarding its ongoing ReSPECT-GBM clinical trial, aimed at assessing the efficacy of its investigational th...






Plus Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com